immunotherapy

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development

Addition of Dr. Amir Jazaeri and Dr. Anna Jonsson Reflects Ernexa’s Strategic Focus on Ovarian Cancer and Autoimmune Disease ProgramsCAMBRIDGE,...

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis

Trial will be conducted by Angel Pharma and will study 12-week dosing of soquelitinib in patients with moderate-to-severe atopic dermatitisSOUTH...

Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer

AGOURA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage...

TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure

WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI), a company working to improve outcomes for patients with solid tumors by...

IMBRUVICA® (ibrutinib) receives positive CHMP opinion for the treatment of patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplant 

Pending the European Commission final decision, regimen offers a new standard of care for eligible MCL patients1,2Positive opinion reinforces Phase...

IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025

ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results...

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

error: Content is protected !!